New Zika vaccine effective in preclinical trials

December 4, 2018 by Tina Shelton, University of Hawaii at Manoa
Zika virus particles (red) shown in African green monkey kidney cells. Credit: NIAID

Researchers at the University of Hawaii medical school have successfully developed a vaccine candidate for the Zika virus, showing that it is effective in protecting both mice and monkeys from the infection.

Demonstrating the effectiveness of their candidate in monkeys (non-human primates) is an important milestone because it typically predicts the vaccine will work in humans, enabling further clinical development.

A strong global initiative to battle Zika has produced more than 30 since outbreaks in 2015-2016 in Brazil linked the infection in some pregnant women to severe birth defects in their newborns. Zika is spread by the bite of infected mosquitos and through sex.

There is no treatment or cure for Zika virus infection nor is any vaccine currently approved for public use.

The proposed vaccine reported by scientists at the John A. Burns School of Medicine (JABSOM) in the journals Frontiers in Immunology and mSphere, via the open access journal of the American Society for Microbiology, is a recombinant subunit vaccine that uses only a small part (protein) of the Zika virus, produced in insect cells.

"We believe our vaccine candidate shows much promise particularly as it showed to require only two immunizations given three weeks apart and is a potentially safer alternative to other candidates already in clinical trials," said Dr. Axel Lehrer, JABSOM Assistant Professor of Tropical Medicine and Infectious Disease. Lehrer thinks the vaccine his team proposes might be safer that other candidate vaccines, especially keeping in mind that constitute a significant part of the target population for a Zika vaccine.

The at JABSOM included two senior graduate students who served as lead authors of the scientific research papers. Liana Medina, whose early training was directly supported by a National Institutes of Health Diversity in Health-Related Research grant, and Honolulu native Albert To are the graduate student lead authors.

Honolulu-based Hawaii Biotech is a key partner in the vaccine development project with UH.

Two of their scientists, Dr. Jaime Horton and David Clements, contributed to the most recent publication demonstrating vaccine efficacy in monkeys, along with collaborators from Bioqual Inc. of Rockville, Maryland, and the Department of Diagnostic Medicine/Pathobiology, Biosecurity Research Institute, College of Veterinary Medicine, at Kansas State University.

"The intense search for a Zika remedy since early 2016 has required us to be agile, and we believe our vaccine candidate research demonstrates that such quick-turnaround results can be achieved in academic and scientific partnerships here in Hawaii," said Dr. Lehrer. "It is incredibly gratifying that two of the scientists we are training to be the future of biomedical science played key roles in gathering, analyzing and reporting their conclusions. We hope Hawaii's citizens find that as inspiring as we do."

Graduate student scientist and research co-author Liana Medina said there were chances to develop new skills at every step along the way. "Having the opportunity to see the vaccine's development from its very first stages as Zika E protein being produced by Dr. Kenji Obadia, at the time also a student in our department, to a vaccine that is efficacious and safe in animal models was a unique learning experience. Being a part of the process allowed me grow as a student in this field," said Medina.

Fellow graduate student and co-author Albert To said the team's results "put us on the world-stage and highlight the talent we have here in Hawaii." He said, "Being involved with this project has given me a glimpse of the type of research and results needed to progress an idea to a potential preventative therapy used by thousands of people worldwide."

JABSOM scientists continue to work to understand the immune responses to the vaccine. They are collaborating with the UH Kapiolani Community College in an effort to create antibodies that can be used as treatments or for improved diagnostic tests for Zika virus. Other Zika-related research at JABSOM also focuses on understanding how Zika can hide undetected in the sex organs of men for an extended period.

Explore further: Translational research leads to potential Zika virus vaccine

More information: Liana O. Medina et al, A Recombinant Subunit Based Zika Virus Vaccine Is Efficacious in Non-human Primates, Frontiers in Immunology (2018). DOI: 10.3389/fimmu.2018.02464

Albert To et al. Recombinant Zika Virus Subunits Are Immunogenic and Efficacious in Mice, mSphere (2018). DOI: 10.1128/mSphere.00576-17

Related Stories

Translational research leads to potential Zika virus vaccine

May 10, 2017
Preclinical results of research by City College of New York scientists and TechnoVax, Inc. in animal models demonstrate favorable outcomes in developing a vaccine against the mosquito-borne Zika virus. The results were announced ...

Team develops a universal vaccine platform that's cheaper and shelf stable

October 5, 2018
Researchers at The University of Texas Medical Branch at Galveston have developed less expensive way to produce vaccines that cuts the costs of vaccine production and storage by up to 80 percent without decreasing safety ...

The first live-attenuated vaccine candidate completely protects mice against Zika infection

April 10, 2017
The first live-attenuated Zika vaccine still in the development stage completely protected mice against the virus after a single vaccination dose, according to new research from The University of Texas Medical Branch at Galveston ...

Pennsylvania firm launches Zika vaccine trial in Puerto Rico

August 29, 2016
A Pennsylvania drug company announced Monday that it has launched a clinical trial of an experimental Zika vaccine in Puerto Rico, the part of the U.S. hardest hit by the mosquito-borne virus.

Video: Responding to a crisis—a vaccine for Zika

March 30, 2017
While a new Gallup poll finds most Americans are not worried about Zika, the recent case of an infected baby born in San Diego demonstrates the virus is a very real issue in this country.

NIH begins clinical trial of live, attenuated Zika vaccine

August 16, 2018
Vaccinations have begun in a first-in-human trial of an experimental live, attenuated Zika virus vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes ...

Recommended for you

Researchers discover unique immune cell likely drives chronic inflammation

December 11, 2018
For the first time, researchers have identified that an immune cell subset called gamma delta T cells that may be causing and/or perpetuating the systemic inflammation found in normal aging in the general geriatric population ...

New light-based technology reveals how cells communicate in human disease

December 11, 2018
Scientists at the University of York have developed a new technique that uses light to understand how cells communicate in human disease.

Macrophage cells key to helping heart repair—and potentially regenerate, new study finds

December 11, 2018
Scientists at the Peter Munk Cardiac Centre have identified the type of cell key to helping the heart repair and potentially regenerate following a heart attack.

Immune cells sacrifice themselves to protect us from invading bacteria

December 11, 2018
Immune systems are working overtime as winter approaches. Stomach flu can turn the strongest individual into a bedridden convalescent. Viruses are spreading in kindergartens. This year's flu is approaching in full swing. ...

Study identifies a key cellular mechanism that triggers pneumonia in humans

December 11, 2018
The relationship between influenza and pneumonia has long been observed by health workers. Its genetic and cellular mechanisms have now been investigated in depth by scientists in a study involving volunteers and conducted ...

Effect of oral alfacalcidol on clinical outcomes in patients without secondary hyperparathyroidism

December 11, 2018
Treatment with active vitamin D did not decrease cardiovascular events in kidney patients undergoing hemodialysis, according to a research group in Japan. They have reported their research results in the December 11 issue ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

GEORGEBELLA
not rated yet Dec 05, 2018
Greetings!!! I am grateful to Dr Larry for curing my Herpes Simplex disease, And i have been living with this disease for 5years and i have taken lot of Root and herbs and Drugs but none were able to cure me, Until i saw a comment on a page where someone testify about this great herbalist and i check his website and i was grateful that he truly cure disease, I am free from my Herpes simplex virus. After contacting Dr Larry in less than 5 days i received my medicine and when i use it for only 21 days i was cured permanently, Contact Dr Larry and find your own cure. I was told he Cures different kind of disease, HIV AIDS, HEPATITIS B, CANCER, DIABETES And many more assurancesolutionhome@gmail.com WhatSApp: +1(424)-261-8520

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.